VOR
Vor Biopharma Inc.
NASDAQ · USHealthcareBiotechnology
$17.45-3.54%
Price as of Jul 20, 2026
VOR financials
Vor Biopharma Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $3.5M | $9.0M |
| Gross profit | $0.00 | $0.00 | -$3.5M | -$9.0M |
| Operating expenses | $371.6M | $121.2M | $122.5M | $84.5M |
| Operating income | -$371.6M | -$121.2M | -$126.0M | -$93.4M |
| Net income | -$696.0M | -$116.9M | -$117.9M | -$92.1M |
| EBITDA | -$693.1M | -$113.4M | -$114.4M | -$83.1M |
| Basic EPS | $-70.50 | $-34.00 | $-35.00 | $-46.60 |
| Diluted EPS | $-70.50 | $-34.00 | $-35.00 | $-46.60 |
| Balance sheet | ||||
| Cash & equivalents | $396.5M | $81.9M | $31.4M | $57.7M |
| Total assets | $464.1M | $142.9M | $209.8M | $299.4M |
| Total liabilities | $628.4M | $46.2M | $59.1M | $48.8M |
| Stockholders’ equity | -$164.3M | $96.7M | $150.7M | $250.6M |
| Total debt | $3.0M | $31.8M | $35.7M | $38.9M |
| Net debt | -$393.5M | -$50.1M | $4.3M | -$18.8M |
| Cash flow | ||||
| Operating cash flow | -$142.7M | -$99.7M | -$100.3M | -$85.1M |
| Capital expenditure | -$941.0K | -$229.0K | -$1.1M | -$8.5M |
| Free cash flow | -$143.7M | -$99.9M | -$101.4M | -$93.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |